J. Fishman

Infectious Diseases · Clinical Infectious Diseases · 2005–2017

A researcher in the Science corpus: 7 papers; trusts 3 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

Whom J. Fishman trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. M. Morrell
  2. Victoria J. Fraser

Who trusts J. Fishman overall

  1. Emily R. M. Sydnor
  2. Trish Perl
  3. M. Pfaller

Papers from J. Fishman's perspective

Ordered by how strongly the researchers J. Fishman trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. (The Lancet)
  2. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. (New England Journal of Medicine)
  3. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (New England Journal of Medicine)
  4. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (New England Journal of Medicine)
  5. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. (Clinical Infectious Diseases)
  6. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. (Journal of Clinical Epidemiology)
  7. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. (Clinical Infectious Diseases)
  8. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (Clinical Infectious Diseases)
  9. Echinocandin antifungal drugs. (The Lancet)
  10. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. (Clinical Infectious Diseases)

Their papers